Skip to main content

Overview

Our lab studies fibrosis, specifically the interactions between mast cells and fibroblasts; mast cells reside in close proximity to fibroblasts. Our goals are identifying new anti-fibrotic targets and designing novel therapeutic compounds to prevent fibrosis.

The goal of the Silver Laboratory is to define the mechanisms by which fibrosis occurs. Fibrosis impacts a significant portion of the global population and is a growing public health concern. A hallmark of fibrosis is the increased expression of fibroblast transforming growth factor-β (TGF-β) and the subsequent activation of collagen genes. Large-scale clinical studies of pharmacologic therapy for inhibiting organ fibrosis have predominantly focused on TGF-β and associated signaling pathways involved in the translation of collagenous peptides. However, due to its multi-functionality, targeting TGF- β signaling has a higher likelihood of adverse effects. Plus, TGF- β is not the only pathway contributing to fibrosis. Not surprisingly then, the preponderance of clinical trial evidence suggests that TGF- β-targeted therapies are only partially beneficial, often with poor tolerability. There is a great need for a deeper understanding of the cellular and molecular mechanisms underlying pathological fibrosis and new therapeutic approaches.

The lab’s research focuses on the interactions between mast cells and fibroblasts, the cells responsible for fibrosis. (Figure 1. see electron micrograph showing spatial relationship between mast cell and fibroblasts). The  association between mast cells and fibroblasts has long been appreciated but the cross-talk and mechanistic interactions between. n them are not well defined. We use parallel in vivo and in vitro functional, biochemical, and cell biological approaches to analyze how mast cells and fibroblasts interact to promote fibrosis.  The Silver lab has identified numerous pro-fibrotic chemicals and vesicles (exosomes) that are released from mast cells that stimulate fibroblasts and fibrosis. Silver’s studies have identified new therapeutic targets for abating fibrosis. Building on our findings we are utilizing in silico drug design to inform novel anti-fibrotic therapeutics. 

Highlights

  1. 1
    Frontiers in medicine · 2023
    PMID: 36910476PMCID: PMC9995661DOISenior author16 citations

Publications

59 publications

Active

1 grant
  • Sub-PI
    Fast Track Phase II - Platform technology to identify and develop first-in-class anti-fibrotic therapeutics through inhibition of collagen CP4H
    National Heart, Lung, and Blood Institute · 2024–2027 · via Adiutrix Therapeutics, LLC· 2 renewals
    R42HL176297-02
Completed grants (4)
  • Sub-PI
    Development of Small Molecule Inhibitors of Collagen Prolyl-4 Hydroxylase (CP4H) to Treat Fibrosis
    NYSTAR · 2024–2025 · via Cornell University - Ithaca
    CUI 235199-01
  • PI
    Development of Novel Drugs to Treat Fibrosis Through Modulation of Collagen Prolyl-4-Hydroxylase
    Daedalus Fund for Innovation (Weill Cornell) · 2020–2023BioPharma Alliance
    DFI 202950-02
  • KP
    Histamine Receptor/Norepinephrine in Cardiac Dysfunction
    National Heart, Lung, and Blood Institute · 2010–2015
    R01HL034215-37EWO
  • PI
    Mast-Cell Renin and Local ANG II Formation
    National Institute of Diabetes and Digestive and Kidney Diseases · 2007–2011
    R01DK060726-08 EW

News mentions